Prevention of bleeding in hemophilia patients with high-titer inhibitors

References

• Brackmann HH, Wallny T. Immune tolerance: high-dose regimen. In: Rodriguez-Merchan EC, Lee CA, editors. Inhibitors in patients with hemophilia. Blackwell Science, Ltd; Oxford, England: 2002. p. 45-8
   Google Scholar
• Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997;19(1):23-7
   PubMed Web of Science ®Google Scholar
• Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of hemophilia monograph series. Available from: www1.wfh.org/publication/files/pdf-1178.pdf [Last accessed September 2004]
   Google Scholar
• White GC, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85(3):560
   PubMed Web of Science ®Google Scholar
• Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004;77(2):187-93
   PubMed Web of Science ®Google Scholar
• Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000;60(3):547-54
   PubMed Web of Science ®Google Scholar
• Hilgartner M, Aledort L, Andes A, et al. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990;30(7):626-30
   PubMed Web of Science ®Google Scholar
• Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80(6):912-18
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19(1):e1-47
   PubMed Web of Science ®Google Scholar
• National hemophilia foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available from: www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007 [Last accessed 4 November 2007]
   Google Scholar
• Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236(4):391-9
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357(6):535-44
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011;9(4):700-10
   PubMed Web of Science ®Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012;10(3):359-67
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013;11(6):1119-27
   PubMed Web of Science ®Google Scholar
• Windyga J, Lissitchkov T, Stasyshyn O, et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level </=2%) haemophilia B. Haemophilia 2014;20(1):15-24
   PubMed Web of Science ®Google Scholar
• Valentino LA, Martinowitz U, Doolas A, et al. Surgical excision of a giant pelvic pseudotumour in a patient with haemophilia A. Haemophilia 2006;12(5):541-4
   Google Scholar
• Antunes SV, Vicari P, Cavalheiro S, et al. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 2003;9(5):573-7
   PubMed Web of Science ®Google Scholar
• Panicker J, Warrier I, Thomas R, et al. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003;9(3):272-8
   PubMed Web of Science ®Google Scholar
• Steen Carlsson K, Hojgard S, Glomstein A, et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003;9(5):555-66
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Donfield SM, Lynn HS, et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001;108(6):E105
   PubMed Web of Science ®Google Scholar
• Pergantou H, Matsinos G, Papadopoulos A, et al. Comparative study of validity of clinical, x-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006;12(3):241-7
   PubMed Web of Science ®Google Scholar
• Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007;13(5):606-12
   PubMed Web of Science ®Google Scholar
• Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102(7):2358-63
   PubMed Web of Science ®Google Scholar
• Leissinger C, Cooper DL, Solem CT. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. Haemophilia 2011;17(6):884-9
   Google Scholar
• Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E, et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004;10(Suppl 2):30-40
   PubMed Web of Science ®Google Scholar
• Rodriguez-Merchan EC. Surgery in haemophilic patients with inhibitors. Haemophilia 2004;10(Suppl 2):1-2
   Google Scholar
• Kreuz W, Escuriola-Ettingshausen C, Mentzer D. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood 2000;96(Suppl):266a
   Google Scholar
• Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003;9(3):261-8
   PubMed Web of Science ®Google Scholar
• DiMichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006;12(4):352-62
   PubMed Web of Science ®Google Scholar
• Leissinger CA, Becton DL, Ewing NP, et al. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007;13(3):249-55
   Google Scholar
• Morfini M, Auerswald G, Kobelt RA, et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007;13(5):502-7
   Google Scholar
• Jimenez-Yuste V, Alvarez MT, Martin-Salces M, et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009;15(1):203-9
   Google Scholar
• Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009;15(3):733-42
   Google Scholar
• Young G, Auerswald G, Jimenez-Yuste V, et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 2012;130(6):864-70
   PubMed Web of Science ®Google Scholar
• Ewing N, Escuriola-Ettingshausen C, Kreuz W. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Haemophilia 2015. [Epub ahead of print]
   Google Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007;5(9):1904-13
   PubMed Web of Science ®Google Scholar
• Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011;365(18):1684-92
   PubMed Web of Science ®Google Scholar
• Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014;20(1):65-72
   PubMed Web of Science ®Google Scholar
• Hoots WK, Ebbesen LS, Konkle BA, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008;14(3):466-75
   Web of Science ®Google Scholar
• Leissenger CA, Gringeri A, Valentino LA, et al. Joint disease and the potential for improved joint health in inhibitor patients who have a good response to aPCC prophylaxis: data from the Pro-FEIBA study. Blood 2012;120(21):Abstract 3374
   Google Scholar
• Gringeri A, Leissinger C, Cortesi PA, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013;19(5):736-43
   Google Scholar
• Stasyshyn O, Antunes S, Mamonov V, et al. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study. Haemophilia 2014;20(5):644-50
   Google Scholar
• Ewenstein BM, Valentino LA, Journeycake JM, et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004;10(5):629-48
   Google Scholar
• Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003;9(1):50-6
   Google Scholar
• Tarantino MD, Lail A, Donfield SM, et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003;9(5):588-92
   Google Scholar
• Bollard CM, Teague LR, Berry EW, et al. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000;6(2):66-70
   Google Scholar
• Valentino LA, Ewenstein B, Navickis RJ, et al. Central venous access devices in haemophilia. Haemophilia 2004;10(2):134-46
   PubMed Web of Science ®Google Scholar
• Morado M, Jimenez-Yuste V, Villar A, et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001;7(6):551-6
   Google Scholar
• van Dijk K, van Der Bom JG, Bax KN, et al. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica 2004;89(2):189-94
   Google Scholar
• Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119(6):1335-44
   PubMed Web of Science ®Google Scholar
• van den Berg HM, Fischer K, Roosendaal G, et al. The use of the Port-A-Cath in children with haemophilia – a review. Haemophilia 1998;4(4):418-20
   Google Scholar
• DiMichele D, Rivard G, Hay C, et al. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004;10(Suppl 4):140-5
   PubMed Web of Science ®Google Scholar
• Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Curr Opin Hematol 2003;10(5):369-74
   Google Scholar
• Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977;2(8044):933
   Google Scholar
• Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors--twenty years’ ‘Bonn protocol’. Vox Sang 1996;70(Suppl 1):30-5
   PubMedGoogle Scholar
• Klintman J, Astermark J, Berntorp E. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol 2010;151(4):381-6
   Google Scholar
• Yada K, Nogami K, Ogiwara K, et al. Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness. J Thromb Haemost 2013;11(5):902-10
   Google Scholar
• Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994;72(1):155-8
   Google Scholar
• DiMichele DM, Kroner BL. The north american immune tolerance registry: practices, outcomes, outcome predictors. Thromb Haemost 2002;87(1):52-7
   PubMed Web of Science ®Google Scholar
• Hay CR. Textbook of hemophilia. In: Lee CA, Berntorp EE, Hoots WK, editors. Inhibitors to factor VIII/IX: treatment of inhibitors–immune tolerance induction. Blackwell Publishing Ltd; Malden, MA: 2005. p. 74-9
   Google Scholar
• Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007;109(2):546-51
   PubMed Web of Science ®Google Scholar
• Allen G, Aledort L. Therapeutic decision-making in inhibitor patients. Am J Hematol 2006;81(1):71-2
   Google Scholar
• Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Haemophilia 2010;16(1):90-100
   Google Scholar
• Gelhorn H, Merikle E, Krishnan S, et al. Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII. Haemophilia 2013;19(1):119-25
   Google Scholar
• Young G, Sorensen B, Dargaud Y, et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013;121(11):1944-50
   Google Scholar